2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1597

Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial
Abstract Number: 2625

Work Productivity in Systemic Lupus Erythematosus: Relationship with Clinical Features
Abstract Number: 1057

Work-Related Behavior and Experiences in Patients with Rheumatoid Arthritis
Abstract Number: 1078

Work-Related Behavior and Experiences in Patients with Systemic Lupus Erythematosus
Abstract Number: 2410

Working Status and Improvements in Work Productivity over Time in an Early Rheumatoid Arthritis (ERA) Cohort
Abstract Number: 46

Xanthine Oxidase Inhibitors and Risk of Type 2 Diabetes in Patients with Gout
Abstract Number: 998

β2 Adrenoceptor Signal Is Augmented in B Cells in the Course of Arthritis to Increase IL-10

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

2014 ACR/ARHP Annual Meeting

Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial

Work Productivity in Systemic Lupus Erythematosus: Relationship with Clinical Features

Work-Related Behavior and Experiences in Patients with Rheumatoid Arthritis

Work-Related Behavior and Experiences in Patients with Systemic Lupus Erythematosus

Working Status and Improvements in Work Productivity over Time in an Early Rheumatoid Arthritis (ERA) Cohort

Xanthine Oxidase Inhibitors and Risk of Type 2 Diabetes in Patients with Gout

β2 Adrenoceptor Signal Is Augmented in B Cells in the Course of Arthritis to Increase IL-10